Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487797 | 0.97 | AKR1C1 (0.65) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2079237 | 0.97 | AKR1C1 (0.65) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3219884 | 0.95 | AKR1C1 (0.62) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL435932 | 0.95 | AKR1C1 (0.62) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL301111 | 0.93 | AKR1C1 (0.53) | AKR1C1APPCYP2C9CYP2C19CYP3A4 | |
| Bromodichloroacetic Acid SCHEMBL7813487 | 0.87 | AKR1C1 (0.53) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1626768 | 0.85 | ALDH1A1 (0.48) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5768673 | 0.85 | AKR1C1 (0.46) | AKR1C1APPCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6505689 | 0.85 | CYP2D6 (0.48) | AKR1C1APPCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL10002509 | 0.85 | LMNA (0.48) | AKR1C1ALDH1A1LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| CN-106957285-B | Amino New cyclobutane derivative, preparation method and its purposes as drug | 皮埃尔法布雷医药公司 | 2019-05-03 | — | — | CN | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| US-5525742-A | IDENTIFICATION OF BIOCHEMICAL COMPONENTS FORMING ATP-SENSITIVE POTASSIUM CHANNELS IN SMOOTH MUSCLE CELLS | THE UPJOHN COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | AKR1C1 1599/4885APP 1915/4885CYP2C9 3052/4885 |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | AKR1C1 277/4885APP 148/4885CYP2C9 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.